Congress should be cautious about turning Most-Favored-Nation drug pricing into permanent law. Codification could lock in an opaque, foreign-reference pricing regime that may deliver headline savings while weakening U.S. biomedical innovation, complicating patient access, and leaving the actual drivers of high out-of-pocket costs untouched.
The case for lower drug costs is compelling. Americans should not face unaffordable prescriptions, and policymakers should demand accountability across the drug supply chain. But MFN is an imprecise remedy: it attempts to lower U.S. prices by tying them to prices in other countries, rather than correcting the market failures that make medicines expensive in the first place.
The administration’s MFN arrangements have reportedly been negotiated privately with individual manufacturers, with limited public information about the covered products, price formulas, and terms. That makes it difficult for Congress to responsibly convert those agreements into a durable national statute. Legislating before those details are transparent would hand policymakers—and patients—a rulebook they cannot fully examine.
Drug development is expensive, slow, and uncertain. Most potential therapies fail, while the successful ones finance future research, clinical trials, manufacturing capacity, and partnerships with universities and emerging biotech companies.
A statutory MFN regime would put U.S. reimbursement at the mercy of foreign governments’ pricing decisions. Those countries often achieve lower prices through health systems, coverage rules, and centralized negotiations that the United States does not replicate. Importing only their price ceilings—not the systems underlying them—could reduce expected returns on high-risk research without producing a coherent domestic drug-pricing system.
That risk is especially serious for therapies with small patient populations or complex scientific pathways, including rare-disease treatments, oncology medicines, and next-generation biologics. When capital becomes scarcer, companies do not merely “absorb” the cost; they narrow pipelines, delay trials, and concentrate on projects with more predictable returns. Analyses of reference-pricing policies warn that lower expected revenue can reduce R&D activity and weaken the university, startup, and industry partnerships that support biotech development.
MFN’s appeal rests on the promise of immediate price relief. Yet a policy focused solely on the price of today’s medicine can impose a cost on tomorrow’s patients: fewer therapies, slower launches, and less investment in difficult diseases.
It also creates the possibility that manufacturers respond by changing launch, pricing, or supply decisions across markets. If a low price in one country becomes the benchmark for the U.S. market, companies may face pressure to raise prices abroad, delay launches in lower-price countries, or challenge the policy in court. Legal disputes delayed the prior 2020 MFN effort, illustrating the uncertainty that can accompany an international-reference pricing mandate.
There is an equity concern as well. Countries with limited resources may lose access to lower-priced medicines if their prices become inputs into an American price-control formula. A U.S. affordability policy should not unintentionally make medicines less affordable elsewhere.
Codifying MFN would also distract from reforms that could lower costs more directly and sustainably. Policymakers should focus on competition and transparency rather than importing foreign price controls.
Congress should pursue reforms that:
– Increase transparency in pharmacy benefit manager rebates, fees, and formulary practices
– Ensure negotiated savings are passed through to patients at the pharmacy counter
– Strengthen generic and biosimilar competition and address practices that delay market entry
– Improve price and coverage transparency so patients can compare costs before filling a prescription
– Support domestic biotech research, clinical-trial infrastructure, and resilient pharmaceutical manufacturing
– Target affordability assistance to patients facing high out-of-pocket costs
These approaches confront the incentives and intermediaries that shape U.S. drug costs. MFN does not. As one policy analysis notes, international reference pricing does not itself address PBM opacity, patent-related barriers to competition, or other structural features of the U.S. market.
Congress’s reluctance to codify MFN should not be mistaken for indifference to drug affordability. It can reflect a necessary recognition that permanent law requires transparency, evidence, and a clear understanding of tradeoffs.
The United States should not respond to real drug-pricing challenges by adopting a policy that risks eroding its capacity to discover, develop, and manufacture the medicines patients will need next. Lowering costs and preserving innovation are not competing goals—but MFN is the wrong vehicle for achieving either one.
About the author Mike Essen: Conservative commentator, radio and podcast host. The Conservative Voice of South Florida!
Please make a small donation to the Tampa Free Press to help sustain independent journalism. Your contribution enables us to continue delivering high-quality, local, and national news coverage.
Sign up: Subscribe to our free newsletter for a curated selection of top stories delivered straight to your inbox.
